Direct comparison
Hospital AI Governance vs Corporate AI Boards
Hospital AI oversight differs from corporate AI boards: Medical Executive Committee ties, CMIO sign-off, IRB boundaries, P&T-style clinical review.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about Hospital AI Governance vs Corporate AI Boards
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
Ask CASRAI answers research-administration questions and cites the passages behind every claim. When our sources don't cover a question, it says so.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Corporate AI Governance Board, Hospital AI Governance Committee compare side by side?
The table below compares Corporate AI Governance Board, Hospital AI Governance Committee across 6 procurement-relevant dimensions, from where authority comes from through what it typically misses.
Side-by-side comparison
| Dimension | Corporate AI Governance Board | Hospital AI Governance Committee |
|---|---|---|
| Where authority comes from | Created by the board of directors or executive leadership, per CASRAI's corporate-board comparison — authority exists because the company charters it, with no external body it must defer to. | Authority is usually delegated from, or exercised alongside, the Medical Executive Committee's existing bylaw authority over the practice of medicine — an AI tool that changes clinical decision support is a practice-affecting change, which routes through MEC-derived authority whether or not a separate AI committee exists. |
| Typical chair | CEO, Chief AI Officer, Responsible Scaling Officer, or general counsel, per NIKOLAI's crosswalk of how frontier labs name their accountable decision-maker. | CMIO where the role exists; otherwise a CMO-CIO co-chair arrangement. The chair is a clinical-informatics role, not a risk, legal, or technology-only role, because clinical-workflow authority is the point. |
| Relationship to research-ethics oversight | Not applicable — no research-subjects jurisdiction exists in a corporate structure. | Must define a clean handoff to the IRB. CASRAI's guide to OHRP's unactioned AI recommendations covers IRB oversight of AI use in human-subjects research specifically — a distinct jurisdiction from clinical-care deployment, and the two bodies need a written rule for which one owns a tool that starts as research and moves to clinical use. |
| Closest internal precedent | None needed — the board is typically the first cross-functional risk body the company has built for exactly this kind of decision. | The hospital has almost always already built this shape for something else — the P&T committee's formulary review cadence, the credentialing and privileging process, and controlled-substance diversion governance are all named-committee, defined-cadence, binding-sign-off structures an AI committee can be modeled on directly. |
| Who holds deployment sign-off | Whoever the charter names — CASRAI's corporate comparison and NIKOLAI's Accountable Decision-Maker element both treat this as the single most important line item to get unambiguous in writing. | Same requirement, harder to satisfy cleanly, because clinical AI sign-off can plausibly be claimed by the MEC, the CMIO, a dedicated AI subcommittee, or the P&T-style clinical review body — without an explicit charter naming one accountable decision-maker, all four can each assume another one made the call. |
| What it typically misses | Values-and-fairness review, per CASRAI's corporate comparison, unless an ethics committee's scope is written in alongside the board's deployment authority. | The research/clinical boundary with the IRB, and a single named accountable decision-maker distinct from "the committee" as a diffuse body — the same documentation gap NIKOLAI's Accountable Decision-Maker element exists to close for frontier AI labs. |
Common questions
Common questions about Corporate AI Governance Board vs Hospital AI Governance Committee
Is a hospital AI governance committee the same thing as IRB oversight of AI?
+
No. They cover different jurisdictions. The IRB oversees AI used in human-subjects research under OHRP/45 CFR 46 — covered in CASRAI's guide to OHRP's unactioned AI recommendations. A hospital AI governance committee oversees AI deployed in clinical care, which is a practice-of-medicine question that runs through Medical Executive Committee authority, not a research-ethics question. A tool can move from one jurisdiction to the other — a research model that gets adopted into clinical workflow — which is why the two bodies need an explicit, written handoff rule rather than an assumed one.
Does the Medical Executive Committee need to personally review every AI tool?
+
Not usually. Most hospitals that have built this out delegate day-to-day review to a dedicated AI governance committee or subcommittee — following the same pattern as P&T-committee delegation of formulary decisions — while the MEC retains final bylaw authority and receives reporting on what the subcommittee approved. What the charter needs to make explicit is that the subcommittee's sign-off is binding, not advisory, or approvals can be effectively re-litigated at the MEC level every time.
Who should be the hospital's named accountable decision-maker for AI sign-off?
+
There is no single correct answer, but there needs to be one written answer. Where a CMIO role exists, that is the most common chair; where it doesn't, a CMO-CIO co-chair pairing is the typical fallback. What matters structurally — the same point NIKOLAI's Accountable Decision-Maker element documents for frontier AI labs — is that one named role is on record as the approver for a given deployment decision, rather than sign-off being attributed to "the committee" as a whole, which lets accountability diffuse when something goes wrong.
Going deeper
